These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 11150018)
1. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. Brown P; Cervenáková L; Diringer H J Lab Clin Med; 2001 Jan; 137(1):5-13. PubMed ID: 11150018 [No Abstract] [Full Text] [Related]
2. Variant Creutzfeldt-Jakob disease and prions in the blood supply. Rohwer RG; Drohan W Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166 [No Abstract] [Full Text] [Related]
4. [Mad cow disease: towards a blood screening test]. Nau JY Rev Med Suisse; 2005 Sep; 1(31):2058. PubMed ID: 16212011 [No Abstract] [Full Text] [Related]
5. Fears grow as blood stocks pass on prions undetected. Hopkin M Nature; 2004 Aug; 430(7001):712. PubMed ID: 15306772 [No Abstract] [Full Text] [Related]
6. Reference materials for the evaluation of pre-mortem variant Creutzfeldt-Jakob disease diagnostic assays. Cooper JK; Ladhani K; Minor PD Vox Sang; 2007 May; 92(4):302-10. PubMed ID: 17456154 [TBL] [Abstract][Full Text] [Related]
7. Research strategies for evaluation of prion partitioning in plasma fractionation: impact of different forms of prion spike on partitioning behaviour. Baron H Dev Biol (Basel); 2002; 108():99-109. PubMed ID: 12220148 [No Abstract] [Full Text] [Related]
8. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy. Brown P Vox Sang; 2005 Aug; 89(2):63-70. PubMed ID: 16101685 [TBL] [Abstract][Full Text] [Related]
10. Variant Creutzfeldt-Jacob disease - the availability of a screening test will be the beginning, not the end, of difficult transfusion-related issues. Sandler SG Curr Opin Hematol; 2006 Nov; 13(6):445-6. PubMed ID: 17053456 [No Abstract] [Full Text] [Related]
11. Feasibility study of a screening assay that identifies the abnormal prion protein PrPTSE in plasma: initial results with 20,000 samples. Guntz P; Walter C; Schosseler P; Morel P; Coste J; Cazenave JP Transfusion; 2010 May; 50(5):989-95. PubMed ID: 20088835 [TBL] [Abstract][Full Text] [Related]
13. Balancing evidence and public opinion in health technology assessments: the case of leukoreduction. Cleemput I; Leys M; Ramaekers D; Bonneux L Int J Technol Assess Health Care; 2006; 22(4):403-7. PubMed ID: 16984672 [TBL] [Abstract][Full Text] [Related]
14. FDA wants more restrictions on donated blood. Mitka M JAMA; 2001 Jul; 286(4):408. PubMed ID: 11466114 [No Abstract] [Full Text] [Related]
15. Blood supplies hit by vCJD fear. Strachan-Bennett S Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624 [No Abstract] [Full Text] [Related]
16. A prototype assay to detect vCJD-infected blood. Gregori L Lancet; 2011 Feb; 377(9764):444-6. PubMed ID: 21295340 [No Abstract] [Full Text] [Related]
17. Technical aspects of the development and validation of tests for variant Creutzfeldt-Jakob disease in blood transfusion. Minor PD Vox Sang; 2004 Apr; 86(3):164-70. PubMed ID: 15078250 [TBL] [Abstract][Full Text] [Related]
18. Comment on validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Lukic A; Mead S; Rudge P; Collinge J Ann Neurol; 2011 Jan; 69(1):212; author reply 212-3. PubMed ID: 21280094 [No Abstract] [Full Text] [Related]
19. Scientists race to develop a blood test for vCJD. Nat Med; 2001 Mar; 7(3):261. PubMed ID: 11231599 [No Abstract] [Full Text] [Related]